

=> d ibib abs hitstr 1-5
 THE ESTIMATED COST FOR THIS REQUEST IS 29.05 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1398815 CAPLUS
 DOCUMENT NUMBER: 151:515287
 TITLE: Spiroazaindoles useful as HIF prolyl hydroxylase
 inhibitors to treat anemia
 INVENTOR(S): Fletcher, Joan M.; Hale, Jeffrey J.; Miao, Shouwu;
 Vachal, Petr
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 33pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009137291	A2	20091112	WO 2009-US41865	20090428
WO 2009137291	A3	20100121		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2008-126895P P 20080508

OTHER SOURCE(S): MARPAT 151:515287


AB The present invention relates to spiroazaindole compds. useful as HIF
 prolyl hydroxylase inhibitors to treat anemia and like conditions. Thus,
 synthesis routes for spiroazaindole compds. are provided in the examples.

IT 1192833-96-7P

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); PROC (Process); USES (Uses)
 (spiroazaindoles useful as HIF prolyl hydroxylase inhibitors to treat
 anemia)

RN 1192833-96-7 CAPLUS

CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-2'(1'H)-one,
 1'-(1,1'-biphenyl)-4-yl-1-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




IT 1192834-07-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (spiroazaindoles useful as HIF prolyl hydroxylase inhibitors to treat anemia)

RN 1192834-07-3 CAPLUS

CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-2'(1'H)-one,
 1'-(1,1'-biphenyl)-4-yl-1-[(3-methyl-2-pyridinyl)methyl]-,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 1192833-96-7
 CMF C30 H28 N4 O



CM 2

CRN 76-05-1
 CMF C2 H F3 O2





L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:143519 CAPLUS
 DOCUMENT NUMBER: 146:229382
 TITLE: Preparation of dipiperazinyl ketones and related analogues as modulators of histamine H3 receptor binding
 INVENTOR(S): Xie, Lingshong; Ochterski, Joseph W.; Gao, Yang; Han, Bingsong; Caldwell, Timothy M.; Xu, Yuelian; Peterson, John M.; Ge, Ping; Ohliger, Robert
 PATENT ASSIGNEE(S): Neurogen Corporation, USA
 SOURCE: PCT Int. Appl., 279pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016496	A2	20070208	WO 2006-US29761	20060728
WO 2007016496	A3	20090430		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006275568	A1	20070208	AU 2006-275568	20060728
CA 2606004	A1	20070208	CA 2006-2606004	20060728
US 20070049571	A1	20070301	US 2006-495986	20060728
EP 1909797	A2	20080416	EP 2006-788999	20060728
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009506987	T	20090219	JP 2008-525081	20060728
PRIORITY APPLN. INFO.:			US 2005-704722P	P 20050802
			WO 2006-US29761	W 20060728

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:229382; MARPAT 146:229382


GI




AB Title compds. I [Z1 and Z2 independently = N or CRa wherein Ra = H, OH, halo, alkyl, etc.; Z3 = N or CRb wherein Rb = absent, H, OH, alkyl, etc.; bonds a and b independently represent single or double bond such that if Z3 = N, then bond a is single bond and at least one bond a or bond b = single bond; W = CR3R4, NR5, COCR3R4, CO2R3R4; R3 and R4 independently = H, alkyl, haloalkyl, etc.; R5 = H, alkyl, haloalkyl, etc.; each m independently = 0-2, such that neither m = 0 if both Z2 and Z3 = N; n = 0-2; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = 0-4 substituents chosen from alkyl and groups that are taken together to form alkylene bridge; R6 = (un)substituted alkanoyl, alkoxy carbonyl, alkenyl, etc.; R7 = 0-4 substituents chosen from alkyl and groups that are taken together to form alkylene bridge], and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of histamine H3 receptor binding. Thus, e.g., II was prepared by acetylation of 1-cyclopentylpiperazine with bromoacetyl bromide followed by N-alkylation of 1-(4-piperazin-1-ylphenyl)ethanone. Details for bioassays are described (no data). I may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

IT 923936-50-9P 923936-98-5P 923937-00-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of dipiperazinyl ketones and related analogs as histamine H3 receptor modulators)


RN 923936-50-9 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-2'(1'H)-one, 1-[2-(4-cyclobutyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



RN 923936-98-5 CAPLUS
CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[1',2'-dihydro-1'-(phenylmethyl)spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1-yl]- (CA INDEX NAME)



RN 923937-00-2 CAPLUS
CN Spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-2'-(1'H)-one, 1-[2-(4-cyclobutyl-1-piperazinyl)-2-oxoethyl]-1'-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:588966 CAPLUS
 DOCUMENT NUMBER: 143:115453
 TITLE: Preparation of spiropiperidines and related compounds as pesticides
 INVENTOR(S): Molleyres, Louis-Pierre; Cassayre, Jerome; Cederbaum, Fredrik; Maienfisch, Peter
 PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
 SOURCE: PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061500	A1	20050707	WO 2004-IB4083	20041209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303618	A1	20050707	AU 2004-303618	20041209
CA 2547814	A1	20050707	CA 2004-2547814	20041209
EP 1694677	A1	20060830	EP 2004-806330	20041209
EP 1694677	B1	20091202		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1894249	A	20070110	CN 2004-80037007	20041209
BR 2004017544	A	20070327	BR 2004-17544	20041209
JP 2007516972	T	20070628	JP 2006-543658	20041209
CN 101544640	A	20090930	CN 2009-10139118	20041209
AT 450538	T	20091215	AT 2004-806330	20041209
MX 2006006212	A	20060809	MX 2006-6212	20060601
ZA 2006004644	A	20071128	ZA 2006-4644	20060606
KR 2006123308	A	20061201	KR 2006-711568	20060612
IN 2006CN02073	A	20070706	IN 2006-CN2073	20060612
US 20070135408	A1	20070614	US 2007-581176	20070129
PRIORITY APPLN. INFO.:			GB 2003-28905	A 20031212
			CN 2004-80037007	A3 20041209
			WO 2004-IB4083	W 20041209

OTHER SOURCE(S): CASREACT 143:115453; MARPAT 143:115453
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [W = (R4)n; n = 0-3; X = (CRa2)p; Z = (CRa2)q; Ra = H, halo, OH, etc.; p = 0-6; q = 0-6; Y = single bond, CO, CS, etc.; R1 = H, alkyl, alkoxy carbonyl, etc.; R2, R3 = H, halo, CN, etc.; R4 = halo, NO2, CN, etc.; R8 = alkyl, alkenyl, alkynyl, etc.; T = 5- or 6-membered heteroarom. ring] and N-oxides were prepared. For example, N-alkylation of piperidine II with 4-chlorocinnamyl chloride afforded spiro piperidine III in 58% yield. In diamoundback moth protection assays, 72-examples of compds. I at 18.2 ppm exhibited at least 80% protection after 5-days.


IT 857730-03-1P 857730-25-7P 857730-26-8P
 857730-27-9P 857730-28-0P 857730-29-1P
 857730-30-4P 857730-31-5P 857730-32-6P
 857730-33-7P 857730-34-8P 857730-35-9P
 857730-36-0P 857730-37-1P 857730-38-2P
 857730-39-3P 857730-40-6P 857730-41-7P
 857730-42-8P 857730-43-9P 857730-44-0P
 857730-45-1P 857730-46-2P 857730-47-3P
 857730-48-4P 857730-49-5P 857730-50-8P
 857730-51-9P 857730-52-0P 857730-53-1P
 857730-54-2P 857730-55-3P 857730-56-4P
 857730-57-5P 857730-58-6P 857730-59-7P
 857730-60-0P 857730-61-1P 857730-62-2P
 857730-63-3P 857730-64-4P 857730-65-5P
 857730-66-6P 857730-67-7P 857730-68-8P
 857730-69-9P 857730-70-2P 857730-71-3P
 857730-72-4P 857730-73-5P 857730-74-6P
 857730-75-7P 857730-76-8P 857730-77-9P
 857730-78-0P 857730-79-1P 857730-80-4P

RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
 SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro piperidines and related compds. as pesticides)

RN 857730-03-1 CAPLUS
 CN Methanone, [6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydro spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-25-7 CAPLUS

CN Ethanone, 1-[1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-5'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-26-8 CAPLUS

CN Ethanone, 1-[5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-27-9 CAPLUS

CN Ethanone, 1-[5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-28-0 CAPLUS

CN Ethanone, 1-[6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-29-1 CAPLUS

CN Ethanone, 1-[6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-30-4 CAPLUS

CN Ethanone, 1-[6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-31-5 CAPLUS

CN Ethanone, 1-[1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-6'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-32-6 CAPLUS

CN Ethanone, 1-[6'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-33-7 CAPLUS

CN Ethanone, 1-[6'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrololo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-34-8 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-5'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrololo[3,2-b]pyridin]-1'-yl]-4-pyridinyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-35-9 CAPLUS

CN Methanone, [5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]-4-pyridinyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-36-0 CAPLUS

CN Methanone, [5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]-4-pyridinyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-37-1 CAPLUS

CN Methanone, [6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]-4-pyridinyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-38-2 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]-4-pyridinyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-39-3 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]-4-pyridinyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-40-6 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-41-7 CAPLUS

CN Methanone, (2-chloro-4-pyridinyl)[1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-42-8 CAPLUS

CN Methanone, (2-chloro-4-pyridinyl)[1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-43-9 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-5'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-44-0 CAPLUS

CN Methanone, (2-chloro-4-pyridinyl)[5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-45-1 CAPLUS

CN Methanone, (2-chloro-4-pyridinyl)[5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-46-2 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-47-3 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-48-4 CAPLUS


CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-6'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 857730-49-5 CAPLUS
CN Methanone, (2-chloro-4-pyridinyl)[6'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 857730-50-8 CAPLUS
CN Methanone, (2-chloro-4-pyridinyl)[6'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-51-9 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydro-6'-methylspiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-52-0 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydro-6'-(trifluoromethyl)spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-53-1 CAPLUS

CN Methanone, (2-chloro-4-pyridinyl)[1',2'-dihydro-6'-(trifluoromethyl)-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-54-2 CAPLUS

CN Methanone, (2-chloro-4-pyridinyl)[1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]-6'-(trifluoromethyl)spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-1'-yl]-(CA INDEX NAME)


Double bond geometry as shown.



RN 857730-55-3 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-5'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-56-4 CAPLUS

CN Methanone, (2,6-dichloro-4-pyridinyl)[5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-57-5 CAPLUS

CN Methanone, (2,6-dichloro-4-pyridinyl)[5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-58-6 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-phenyl-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-59-7 CAPLUS

CN Methanone, [6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-60-0 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-61-1 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-62-2 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-6'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-63-3 CAPLUS

CN Methanone, (2,6-dichloro-4-pyridinyl)[6'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-64-4 CAPLUS

CN Methanone, (2,6-dichloro-4-pyridinyl)[6'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-65-5 CAPLUS

CN Methanone, [6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-5'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrololo[3,2-b]pyridin]-1'-yl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-66-6 CAPLUS

CN Methanone, [1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-5'-fluoro-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrololo[3,2-b]pyridin]-1'-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-67-7 CAPLUS

CN Methanone, [5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-68-8 CAPLUS

CN Methanone, [5'-fluoro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-69-9 CAPLUS

CN Methanone, [6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1',2'-dihydrospiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-70-2 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-71-3 CAPLUS

CN Methanone, [6'-chloro-1',2'-dihydro-1-[(2E)-3-[4-(trifluoromethoxy)phenyl]-2-propen-1-yl]spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridin]-1'-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-72-4 CAPLUS

CN Spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridine]-1'-(2'H)-carboxamide, 1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-N-[(2-chloro-5-thiazolyl)methyl]-5'-fluoro- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-73-5 CAPLUS

CN Spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide,
N-[(2-chloro-5-thiazolyl)methyl]-5'-fluoro-1-[(2E)-3-[4-
(trifluoromethyl)phenyl]-2-propenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-74-6 CAPLUS

CN Spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide,
N-[(2-chloro-5-thiazolyl)methyl]-5'-fluoro-1-[(2E)-3-[4-
(trifluoromethoxy)phenyl]-2-propenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-75-7 CAPLUS

CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1'-(2'H)-carboxamide,
6'-chloro-1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-N-[(2-chloro-5-
thiazolyl)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-76-8 CAPLUS

CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1'-(2'H)-carboxamide,
6'-chloro-N-[(2-chloro-5-thiazolyl)methyl]-1-[(2E)-3-[4-
(trifluoromethyl)phenyl]-2-propen-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-77-9 CAPLUS

CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide,
6'-chloro-N-[(2-chloro-5-thiazolyl)methyl]-1-[(2E)-3-[4-
(trifluoromethoxy)phenyl]-2-propen-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 857730-78-0 CAPLUS


CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide,
1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-N-[(2-chloro-5-thiazolyl)methyl]-
6'-fluoro- (CA INDEX NAME)

Double bond geometry as shown.




RN 857730-79-1 CAPLUS
CN Spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide,
N-[(2-chloro-5-thiazolyl)methyl]-6'-fluoro-1-[(2E)-3-[4-
(trifluoromethyl)phenyl]-2-propen-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 857730-80-4 CAPLUS
CN Spiro[piperidine-4,3'-[3H]pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide,
N-[(2-chloro-5-thiazolyl)methyl]-6'-fluoro-1-[(2E)-3-[4-
(trifluoromethoxy)phenyl]-2-propen-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



IT 857730-15-5P 857730-16-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of spiropiperidines and related compds. as pesticides)
 RN 857730-15-5 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1-carboxylic acid,
 6'-chloro-1',2'-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857730-16-6 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1-carboxylic acid,
 6'-chloro-1'-(2-chloro-4-pyridinyl)carbonyl]-1',2'-dihydro-,
 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:335409 CAPLUS
 DOCUMENT NUMBER: 132:334474
 TITLE: Preparation of spiroindolines as Y5 receptor antagonists
 INVENTOR(S): Gao, Ying-duo; Macneil, Douglas J.; Yang, Lihu; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.
 SOURCE: PCT Int. Appl., 130 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027845	A1	20000518	WO 1999-US26447	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2350714	A1	20000518	CA 1999-2350714	19991108
US 6191160	B1	20010220	US 1999-436120	19991108
EP 1129089	A1	20010905	EP 1999-971808	19991108
EP 1129089	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AU 756797	B2	20030123	AU 2000-14732	19991108
AT 314371	T	20060115	AT 1999-971808	19991108
ES 2255330	T3	20060616	ES 1999-971808	19991108
US 6313298	B1	20011106	US 2000-656698	20000907
US 20020058813	A1	20020516	US 2001-896940	20010629
US 6495559	B2	20021217		
US 6638942	B1	20031028	US 2002-228250	20020826
US 20040063942	A1	20040401	US 2003-624414	20030721


PRIORITY APPLN. INFO.:

US 1998-107835P	P 19981110
US 1999-436120	A3 19991108
WO 1999-US26447	W 19991108
US 2000-656698	A3 20000907
US 2001-896940	A3 20010629
US 2002-228250	A3 20020826

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:334474

GI




AB The title compds. I [V, W, X, Z = CH, N; R1 = H, alkyl, etc.; R2 = CHO, etc.; R3 = H, alkyl; Ar = aryl, heteroaryl; R4, R5 = H, nitro, etc.] are prepared I are useful in the treatment of obesity and the complications associated therewith. 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide at 3 mg/kg suppressed bovine pancreatic polypeptide-induced food intake in rats. Formulations are given.


IT 268537-71-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of spiroindolines as Y5 receptor antagonists)

RN 268537-71-9 CAPLUS


CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine]-1-carboxamide, 1',2'-dihydro-1'-(methylsulfonyl)-N-(5-phenyl-2-pyrazinyl)- (CA INDEX NAME)



IT 268538-35-8P 268538-36-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of spiroindolines as Y5 receptor antagonists)
 RN 268538-35-8 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine],
 1',2'-dihydro-1-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 268538-36-9 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine],
 1',2'-dihydro-1-[(4-methoxyphenyl)methyl]-1'-(methylsulfonyl)- (CA INDEX
 NAME)



OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1995:752281 CAPLUS
 DOCUMENT NUMBER: 123:339807
 ORIGINAL REFERENCE NO.: 123:60991a,60994a
 TITLE: Design and synthesis of a conformationally constrained analog of the bis(heteroaryl)piperazine (BHAP) HIV-1 reverse transcriptase inhibitor atevirdine
 Genin, Michael J.; Chidester, Constance G.; Rohrer, Douglas C.; Romero, Donna L.
 Med. Chem. Res., Phys. Anal. Chem., Kalamazoo, MI, 49001, USA
 AUTHOR(S):
 CORPORATE SOURCE:
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(16), 1875-80
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 123:339807
 GI




AB The design and synthesis of a novel conformationally constrained spiro analog of the BHAP class of HIV-1 reverse transcriptase inhibitors, I,


based on the mol. modeling and the x-ray crystal structure of the clin. candidate atevirdine, is described.

IT 170752-14-4P 170752-15-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of the indolylcarbonylspiropiperidinepyrrolopyridine derivative, a conformationally constrained analog of BHAP HIV-1 reverse transcriptase inhibitor atevirdine)

RN 170752-14-4 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-2'(1'H)-one, 1'-ethyl-1-(phenylmethyl)- (CA INDEX NAME)




RN 170752-15-5 CAPLUS
 CN Spiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridine], 1'-ethyl-1',2'-dihydro-1-(phenylmethyl)- (CA INDEX NAME)



IT 170752-11-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (design and synthesis of the indolylcarbonylspiropiperidinepyrrolopyridine derivative, a conformationally constrained analog of BHAP HIV-1 reverse transcriptase inhibitor atevirdine)

RN 170752-11-1 CAPLUS
 CN Methanesulfonamide, N-[2-[(1'-ethyl-1',2'-dihydrospiro[piperidine-4,3'-(3H)pyrrolo[3,2-b]pyridin]-1-yl)carbonyl]-1H-indol-5-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 11:27:12 ON 25 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:27:31 ON 25 MAR 2010

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 72 S L1 FULL


FILE 'CAPLUS' ENTERED AT 11:28:27 ON 25 MAR 2010

L4 5 S L3

=> d 11

L1 HAS NO ANSWERS

L1 STR



10/581,176

Structure attributes must be viewed using STN Express query preparation.

=>